
    
      Subjects satisfying the eligibility criteria will be assigned to 1 of the following cohorts
      (which are enrolling in parallel) based on their eligibility:

        -  Cohort 1 (subjects with anemia only that are not currently receiving RBC transfusions) -
           Cohort 2: (subjects that are RBC-transfusion dependent)

        -  Cohort 3A: (subjects on ruxolitinib as part of their standard of care therapy that have
           anemia only)

        -  Cohort 3B: (subjects on ruxolitinib as part of their standard of care therapy that are
           RBC-transfusion dependent) Overall, the study will enroll approximately 100 subjects
           worldwide.
    
  